ERBB2 and breast cancer: Antitumor activity of IL-15 was evaluated in two murine breast cancer models, mouse Her2/neu+ and 4T1-luc mammary cancers treated with systemic administration and intratumor delivery of plasmid IL-15/IL-15Rα, respectively.